Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 December 2018: Original Paper  

Correlation Between Stem and Progenitor Cells Number and Immune Response in Patients After Allogeneic Kidney Transplant

Jerzy Sieńko BCE 1*, Maciej Kotowski CDE 1,2, Edyta Paczkowska BC 2, Anna Sobuś CDE 2, Karol Tejchman CD 1, Jarosław Piątek CF 3, Ewa Pilichowska ADF 1, Karolina Kędzierska-Kapuza DF 4, Marek Ostrowski DF 1

DOI: 10.12659/AOT.912686

Ann Transplant 2018; 23:874-878

0 Comments

Abstract

BACKGROUND: Stem and progenitor cells are of great interest in all medical procedures involving tissue regeneration. There is a consensus that the use of stem cells after solid organ transplantation may play a role in tissue repair and in immunosuppression. The aim of this study was to determine possible relations between stem cell count and the immune response in a group of patients after kidney transplantation.

MATERIAL AND METHODS: The study was conducted on a group of 100 patients who underwent kidney transplantation. The following phenotypic markers of the studied cell subpopulations were adopted: Treg cells (CD3+CD4+CD25high), circulating hematopoietic cells (CD34+CD133+CD45+CD38–), and non-hematopoietic cells (Lin–CXCR4+CD133–CD45–). Cell subpopulations were assessed using LSRII flow cytometer (BD Biosciences, San Jose, CA, USA).

RESULTS: Positive correlation was observed between non-hematopoietic stem cells percentage and recipient’s platelets count (P=0.04). Moreover, a higher percentage of non-hematopoietic cells was accompanied by lower numbers of B lymphocytes (P=0.03) and Treg cells (P=0.02).

CONCLUSIONS: Our study revealed significant associations between the intensity of ongoing immune response processes and tissue damage, and the release of stem and progenitor cells into circulation. These findings suggest their role in the stimulation of protective processes in terms of graft regeneration.

Keywords: Kidney Transplantation, Renal Insufficiency, Chronic, T-Lymphocytes, Regulatory

Background

End-stage renal disease (ESRD) is a life-threatening condition which develops as a consequence of advanced chronic kidney disease. There have been 3 approaches to renal replacement therapy (RRT): peritoneal dialysis, hemodialysis, and allogeneic kidney transplantation [1]. Of these methods, only transplantation allows for the full substitution of the functions of a healthy kidney and significantly increases the quality of life in patients previously undergoing dialysis [2]. In Poland in 2016, 1028 patients received a kidney transplant [3]. Despite the superiority of this method, the issue of acute and chronic rejection of transplants as a consequence of the activity of the recipient’s immune system is still not fully understood. Episodes of acute transplant rejection may in turn lead to chronic organ rejection, which decreases allograft half-life. To avoid rejection, immunosuppressive drugs are administered in high doses, which may lead to various complications [4].

The grafting itself and the subsequent immunosuppressive therapy have a significant influence on immune system regulation. Disruption of immune homeostasis may lead to the development of inflammatory changes and promote transplant rejection [5].

Stem and progenitor cells are of great interest in all medical procedures involving tissue regeneration. There is a consensus that the use of stem cells after solid organ transplantation may play a role in tissue repair and in immunosuppression. Multiple studies have investigated the role of donor bone marrow-derived stem cell injections in suppressing the immune processes leading to organ rejection [6,7]. However, the response of the immune system to circulating stem and progenitor cells and the role of these cells in the recipient’s body remains unclear.

The objective of this retrospective analysis was to investigate the correlation between concentrations of stem and progenitor cells of both hematopoietic and non-hematopoietic lineages and cells responsible for the regulation of immune response after allogeneic kidney transplantation.

Material and Methods

BIOCHEMICAL TESTS AND MORPHOLOGY:

All blood samples obtained from transplant recipients were tested for urea, creatinine, uric acid, glucose and potassium, magnesium and calcium ions. Moreover, a standard morphology was performed to assess the count of red blood cells (RBCs), white blood cells (WBCs), and platelets.

B LYMPHOCYTES COUNT ASSESSMENT:

To assess the overall number of B lymphocytes we used the BD Tritest CD3CD19CD45 (BD Biosciences, San Jose, CA, USA). The acquisition was performed using an LSRII flow cytometer (BD Biosciences, San Jose, CA, USA) with FACS Diva 6.2. For each test 1×104 cells were collected. Total cell count was presented as the number of cells per 1 μL of whole blood.

:

To investigate the population of circulating Treg lymphocytes in whole blood we isolated mononuclear cells using density gradient centrifuging with Ficoll-Histopaque (Sigma, St. Louis, MO, USA). Obtained cells were then incubated with monoclonal antibodies against antigens CD4 (conjugated with FITC), CD 3 (conjugated with PE), and CD 25 (conjugated with APC). The percentage of Treg cells representing phenotype CD3+CD4+CD25high was assessed using the LSRII flow cytometer (BD Biosciences, San Jose, CA, USA). In each sample 5×104 cells were collected.

ANALYSIS OF CIRCULATING STEM/PROGENITOR CELLS:

To assess the amount of circulating hematopoietic (CD34+CD133+CD45+CD38) and non-hematopoietic (LinCXCR4+CD133CD45) stem and progenitor cells the blood sample was lysed to eliminate RBCs using BD PharM Lyse Ammonium Chloride Lysing Reagent (BD Biosciences, San Jose, CA, USA). Obtained nuclear cells were then incubated with monoclonal antibodies against CD34 (conjugated with FITC), CD45 (conjugated with PE), CD133 (conjugated with APC), and CD38 (conjugated with PECγ7) for hematopoietic cells assessment and with antibodies against antigens characteristic for lineage cells (CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, CD235a – conjugated with FITC), CXCR4 (conjugated with APC), CD133 (conjugated with PE), and CD45 (conjugated with PECγ7) to assess the percentage of non-hematopoietic cells. Isotype controls were matched to each analysis. To analyze the samples, the LSRII flow cytometer (BD Biosciences, San Jose, CA, USA) was used.

STATISTICAL ANALYSIS:

Since most of the results deviated from normal distribution in the statistical analysis, we used the nonparametric U Mann-Whitney test to compare the differences between the tested parameters. As a threshold of statistical significance, we accepted a P value <0.05. A P value between 0.05 and 0.1 was treated as being on the threshold of statistical significance. All analyses were carried out using Statistica 10.

Results

BIOCHEMICAL BLOOD TEST AND MORPHOLOGY:

A summary of morphology and biochemical tests is presented in Table 1.

CORRELATION BETWEEN HEMATOPOIETIC AND NON-HEMATOPOIETIC CELLS PERCENTAGE AND SELECTED PARAMETERS:

We observed a significant positive correlation between the percentage of circulating hematopoietic cells and recipient’s age (P=0.02), and a correlation with body mass index (BMI) on the border of significance (P=0.1).

When it comes to non-hematopoietic cells, a positive correlation was observed between cells percentage and recipient’s platelets count (P=0.04). Moreover, a higher percentage of non-hematopoietic cells was accompanied by lower numbers of B lymphocytes (P=0.03) and Treg cells (P=0.02). Correlation analysis is summarized in Table 2.

Discussion

B cells are responsible mostly for alloimmune antibody-mediated transplant rejection reaction. They take part in presenting antigens to T cells and the production of specific antibodies [8]. It has been proposed that B cells are partially responsible for the pathology of graft loss. A study conducted on mice showed that the adaptive immune system takes part in the thickening of the intima, and therefore leads to arteriosclerotic changes in graft vessels [9]. On the other hand, interestingly, is has been reported that an increase in transitional B lymphocytes count in a short time period after grafting (7 days) followed by a significant decrease in their number and consequent repopulation during the year after transplantation is associated with lower incidence of graft rejection [10]. Another study, enrolling patients with operational tolerance (normal graft function and immunocompetent immune system after immunosuppressive drugs withdrawal), found that patients who develop chronic transplant rejection are characterized by lower counts of B cells than those with operational tolerance [11]. In our study we observed decreased B cells count in older patients, which may reflect natural impairment of the immune response with age, which in the case of transplant rejection risk might play a protective role. When it comes to correlation between count of hematopoietic stem cells and B cells we did not observe any significant associations. However, the count of non-hematopoietic cells, which may be released to circulation in response to tissue injury, also in cases of chronic endothelial damage in progression of arteriosclerotic changes, was negatively correlated with B cells count. This may support the previous findings [12–14] and suggest that decreased B lymphocytes count in a long-time period after grafting might precede and herald graft changes resulting from chronic rejection.

T regulatory lymphocytes, characterized by CD3+CD4+CD25high phenotype [15], were the first to be described as immunoregulatory cells with activity other than immune response stimulation [16]. They suppress other subpopulations of T cells and therefore prevent various autoimmune diseases. Studies on mice have shown that Tregs tend to protect them from autoimmunity in a dose-dependent manner [17], and mice lacking the transcription factor specific for Treg cells – FoxP3 – developed a fatal lymphoproliferative disorder [18]. This cell population is capable of suppressing both innate and adaptive immune response. Tregs therapy has been proposed as a potential way to promote allograft survival. Their ability to maintain function during ex vivo expansion has made them a promising tool in approaches to stimulate self-tolerance. Tregs have been successfully used in preventing graft-versus-host disease in human trials [19–21]. In the presented study we described a negative correlation between the percentage of circulation stem/progenitor cells and Treg cells count. This lower concentration of cells inducing immunotolerance has also been reported in other studies in patients after grafting [22]. The same study also suggested that patients with acute rejection after transplantation had lower counts of Tregs before the procedure in comparison to recipients that did not undergo acute rejection [22].

Increased number of circulating non-hematopoietic stem and progenitor cells was accompanied by increased number of platelets in collected blood samples, which may indicate the role of these cells in the endogenous regeneration of the transplanted organ.

Platelets play an important role in the processes occurring in the human body after organ transplantation. Number of platelets correlates with concentration of cells responsible for immunological reaction, as it was previously described [23]. Chronic kidney disease causes uremic platelets dysfunction, but effective transplantation, resulting in the immediate function of the transplanted kidney, leads to normalization of platelet function [24]. Therapies focused on increasing the number of platelets and modification of their function in the peri-transplantation period, are seriously considered [25]. Until now, cellular therapies supporting organ transplantation, have been used most often after kidney transplantation [26]. Therefore, the relationship between the number of platelets and non-hematopoietic stem cells, described in this paper, is of particular importance.

Conclusions

Our study revealed significant associations between the intensity of ongoing immune response processes and tissue damage, and the release of stem and progenitor cells into circulation. These findings suggest their role in the stimulation of protective processes in terms of graft regeneration.

References

1. Moist LM, Lok CE, Incident dialysis access in patients with end-stage kidney disease: what needs to be improved: Semin Nephrol, 2017; 37(2); 151-58, pmid: 28410649

2. Tonelli M, Wiebe N, Knoll G, Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes: Am J Transplant, 2011; 11(10); 2093-109, pmid: 21883901

3. : Polish Organization and Coordination Center for Politating Transplantation “Poltransplant” Bulletin, 2017

4. Katabathina V, Menias CO, Pickhardt P, Complications of immunosuppressive therapy in solid organ transplantation: Radiol Clini North Am, 2016; 54(2); 303-19

5. Hu M, Wang YM, Wang Y, Regulatory T cells in kidney disease and transplantation: Kidney Int, 2016; 90(3); 502-14, pmid: 27263492

6. Leventhal J, Abecassis M, Miller J, Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome: Transplantation, 2013; 95(1); 169-76, pmid: 23222893

7. Trivedi HL, Vanikar AV, Modi PR, Allogeneic hematopoietic stem-cell transplantation, mixed chimerism, and tolerance in living related donor renal allograft recipients: Transplant Proc, 2005; 37(2); 737-42, pmid: 15848518

8. Nouël A, Simon Q, Jamin C, Regulatory B cells: An exciting target for future therapeutics in transplantation: Front Immunol, 2014; 5; 11, pmid: 24478776

9. Steger U, Ensminger S, Bushell A, Investigation into the onset and progression of transplant arteriosclerosis in a mice aortic retransplantation model: Microsurgery, 2008; 28(3); 182-86, pmid: 18253942

10. Svachova V, Sekerkova A, Hruba P, Dynamic changes of B-cell compartments in kidney transplantation: Lack of transitional B cells is associated with allograft rejection: Transpl Int, 2016; 29(5); 540-48, pmid: 26839984

11. Silva HM, Takenaka MC, Moraes-Vieira PM, Preserving the B-cell compartment favors operational tolerance in human renal transplantation: Mol Med, 2012; 18; 733-43, pmid: 22252714

12. Le Texier L, Thebault P, Lavault A, Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile: Am J Transplant, 2011; 11(3); 429-38, pmid: 21114655

13. Nouël A, Ségalen I, Jamin C, B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection: Kidney Int, 2014; 85(3); 590-99, pmid: 24284517

14. Cascalho MI, Chen BJ, Kain M, The paradoxical functions of B cells and antibodies in transplantation: J Immunol, 2013; 190(3); 875-79, pmid: 23335803

15. Dasgupta A, Saxena R, Regulatory T cells: A review: Natll Med J India, 2012; 25(6); 341-51

16. Gershon RK, Kondo K, Cell interactions in the induction of tolerance: The role of thymic lymphocytes: Immunology, 1970; 18(5); 723-37, pmid: 4911896

17. Sakaguchi S, Sakaguchi N, Asano M, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases: J Immunol, 1995; 155(3); 1151-64, pmid: 7636184

18. Brunkow ME, Jeffery EW, Hjerrild KA, Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse: Nat Genet, 2001; 27(1); 68-73, pmid: 11138001

19. Cohen JL, Trenado A, Vasey D, CD4(+)CD25(+) immunoregulatory T cells: New therapeutics for graft-versus-host disease: J Exp Med, 2002; 196(3); 401-6, pmid: 12163568

20. Hoffmann P, Ermann J, Edinger M, Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation: J Exp Med, 2002; 196(3); 389-99, pmid: 12163567

21. Nikoueinejad H, Sharif MR, Amirzargar A, Regulatory T cells as a therapeutic tool to induce solid-organ transplant tolerance: Current clinical experiences: Exp Clin Transplant, 2013; 11(5); 379-87, pmid: 23902519

22. Karczewski M, Karczewski J, Kostrzewa A, The role of Foxp3+ regulatory T cells in kidney transplantation: Transplant Proc, 2009; 41(5); 1527-29, pmid: 19545671

23. Sieńko J, Kotowski M, Safranow K, Role of platelets in the modulation of kidney allograft recipients’ immune systems: Ann Transplant, 2013; 18; 76-81, pmid: 23792505

24. Kennedy C, Wong L, Sexton DJ, Successful kidney transplantation normalizes platelet function: Clin Kidney J, 2018; 11(4); 574-80, pmid: 30087773

25. Takahashi K, Nagai S, Sawfan M, Thrombocytopenia after liver transplantation: Should we care?: World J Gastroenterol, 2018; 24(13); 1386-97, pmid: 29632420

26. Garakani R, Saidi RF, Recent progress in cell therapy in solid organ transplantation: Int J Organ Transplant Med, 2017; 8(3); 125-31, pmid: 28924460

In Press

Original article  

Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...

Ann Transplant In Press; DOI: 10.12659/AOT.951568  

Original article  

Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.950589  

Database Analysis  

Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...

Ann Transplant In Press; DOI: 10.12659/AOT.950289  

Original article  

Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...

Ann Transplant In Press; DOI: 10.12659/AOT.950997  

Most Viewed Current Articles

24 Aug 2021 : Review article   18,372

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

05 Apr 2022 : Original article   14,731

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   14,244

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

29 Dec 2021 : Original article   13,752

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358